课题基金 / 基金详情

PHASE I TRIAL OF BIZELESIN USING SINGLE BOLUS INFUSION EVERY 28 DAYS

PHASE I TRIAL OF BIZELESIN USING SINGLE BOLUS INFUSION EVERY 28 DAYS
每 28 天一次推注的 BIZELESIN 的 I 期试验
批准号：
6586844
负责人：
ERIC K ROWINSKY
金额：
$23.48万
依托单位：
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
依托单位国家：
美国
项目类别：
财政年份：
2001
资助国家：
美国
项目状态：
已结题
起止时间：
2001-12-01 至 2002-11-30
来源：
https://reporter.nih.gov/project-details/6586844
关键词：
antineoplastics clinical research clinical trial phase I dosage drug screening /evaluation human subject human therapy evaluation injection /infusion neoplasm /cancer chemotherapy

项目摘要

项目成果

ERIC K ROWINSKY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The purposes of this study are to determine the maximum tolerated dose of bizelesin given as a ten minute infusion and repeated every 28 days; to determine the qualitative and quantitative toxicities of bizelesin given as a ten minute infusion; to characterize the pharmacokinetics; to determine the recommended dose; and to collect information about the antitumor effects of bizelesin in patients with advanced cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ph I Study Of BMS-247550 In PTS with advanced Neoplasms
Phase II Pharmacologic/Biologic Study of Thalidomide
Ph I Pharmacokinetics of NSC-655649/Cisplatin/G-CSF
PHASE I TRIAL OF LY231514 IN PATIENTS W/ VARYING DEGREES OF RENAL FUNCTION
海外基金